IDEAYA to Participate in Upcoming September 2020 Investor Relations Events
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine company focusing on oncology, announced its participation in several investor relations events in September 2020. Key events include:
- JP Morgan CEO Series on September 8
- Citi 15th Annual BioPharma Conference on September 9
- RW Baird Global Health Care Conference on September 10
- H.C. Wainwright 22nd Annual Global Investment Conference on September 14
- Cantor Fitzgerald Global Healthcare Conference on September 17
Live webcasts of the events will be available on their website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that management will present at the following upcoming investor relations events.
- JP Morgan CEO Series
Fireside Chat hosted by Analyst Anupam Rama
Tuesday, September 8, 2020 at 12:00pm ET
- Citi 15th Annual BioPharma Conference
Company Panel: Precision Targeted Drugs in Oncology hosted by Analyst Mohit Bansal
Wednesday, September 9th at 11:40am ET
- RW Baird Global Health Care Conference
Fireside Chat hosted by Analyst Madhu Kumar
Thursday, September 10th at 3:45pm ET
- H.C. Wainwright 22nd Annual Global Investment Conference
Company Presentation
Monday, September 14th at 11:30am ET
- Cantor Fitzgerald Global Healthcare Conference
Company Presentation
Thursday, September 17th at 4:40pm ET
A live audio webcast of each presentation will be available by visiting the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/news-events/investor-calendar. A replay of the webcasts will be available for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing. IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on August 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-to-participate-in-upcoming-september-2020-investor-relations-events-301120557.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What events will IDEAYA Biosciences participate in during September 2020?
When will IDEAYA present at the JP Morgan CEO Series?
What is the focus of IDEAYA's presentations?
How can I access the webcasts of IDEAYA's presentations?
What is the stock symbol for IDEAYA Biosciences?
